Controlled Double-Blind Trial of Nifedipine in the Treatment of Raynaud's Phenomenon

Richard J. Rodeheffer, James A. Rommer, Fredrick Wigley, Craig R. Smith

Research output: Contribution to journalArticlepeer-review

187 Scopus citations


Raynaud's phenomenon may cause severe digital pain and functional disability, particularly in patients with underlying connective-tissue disease. The treatment of this condition is difficult.1 Nifedipine, a slow calcium-channel antagonist, causes vascular smooth-muscle relaxation and relief of arterial vasospasm.2 3 4 Nifedipine-induced vasodilation has been shown to result in a fall in peripheral vascular resistance and an increase in peripheral blood flow.5 Nifedipine increases the skin blood flow by 50 to 150 per cent in normal persons and has also been shown in vitro to inhibit norepinephrine-induced vasospasm of rabbit and human peripheral arteries and veins.6,7 The calcium-channel blockers nifedipine and verapamil have.

Original languageEnglish (US)
Pages (from-to)880-883
Number of pages4
JournalNew England Journal of Medicine
Issue number15
StatePublished - Apr 14 1983

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Controlled Double-Blind Trial of Nifedipine in the Treatment of Raynaud's Phenomenon'. Together they form a unique fingerprint.

Cite this